You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Biphase Extended Release Tablet Formulation for Nerve Agent Pretreatment

    SBC: Zymeron Corporation            Topic: CBD181004

    Nerve agents exert their toxic effect by binding to and inactivating enzyme acetylcholinesterase, a key enzymatic regulator of cholinergic neurotransmission. The binding becomes irreversible after a varying amount of time with nerve agents and this aging process limits the treatment window of oxime reactivators. To enhance the current antidote treatment of nerve agent autoinjectors, a pyridostigmi ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  2. A Next Generation, High-Precision, Field Drug Detection System

    SBC: SensoDX II, LLC            Topic: A16AT008

    The synthetic opioids fentanyl and carfentanil pose an imminent national security threat, given the ease with which they can be obtained, their low lethal doses, and their potential for weaponized use. The purpose of this agreement is to adapt SensoDx’s high-performance miniaturized diagnostics platform based on a programmable bio-nano-chip, with embedded artificial intelligence, to enable U.S. ...

    SBIR Phase II 2019 Department of DefenseOffice for Chemical and Biological Defense
  3. A High-Throughput Blood Esterase Panel Assay

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD10108

    Organophosphorus chemical warfare nerve agents (OP-CWA) are attractive to terrorist groups and rogue states as an inexpensive and accessible technology for chemical warfare. OP-CWA and organophosphate pesticides cause severe neurological symptoms and death by inhibiting the enzyme acetylcholinesterase (AChE); the resulting excess acetylcholine accumulates and overstimulates the human or animal bo ...

    SBIR Phase I 2010 Department of DefenseOffice for Chemical and Biological Defense
  4. Blood Brain Barrier Drug Delivery of Therapeutics for Chemical Warfare Agents

    SBC: IMPEL NEUROPHARMA, INC.            Topic: CBD10109

    This program plans to develop a drug delivery system that provides maximum oxime drug exposure and improve cholinesterase reactivation in the brain and tissues of central nervous system (CNS) of a warfighter after exposure to organophosphate (OP) poisoning. The greatest need for improvement in cholinesterase reactivation is the ability to deliver charged cholinesterase reactivators to the CNS tha ...

    SBIR Phase I 2010 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government